Using univariate analysis, predictors for poor overall survival of CHB-related HCC patients included: advanced BCLC stage (hazard ratio, 2.04 [95% confidence interval, 1.76–2.36], p < 0.001), NAs post-HCC or NAs naïve (1.36 [1.12–1.65], P < 0.01), serum AFP ≥ 400 ng/ml (1.34 [1.02–1.75], P < 0.05), serum ALT ≥ 64 IU/L (1.66 [1.24–2.21], P < 0.01), serum AST ≥ 40 IU/L, (2.5 [1.84–3.42], P < 0.001), total bilirubin ≥ 24 μmol/L (2.01 [1.54–2.63], P < 0.001), direct bilirubin ≥ 6.8 μmol/L (2.46 [1.89–3.21], P < 0.001) and HBV DNA ≥ 104 copies/ml (1.64 [1.24–2.16], P < 0.001) (Table 4). This evidence concerns the gene AFP and hepatocellular carcinoma.